Breztri Aerosphere is a once-daily, single-inhaler triple therapy approved for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). It combines an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA) [1].
What is in Breztri Aerosphere?
Breztri Aerosphere contains three active ingredients: budesonide, a corticosteroid that reduces airway inflammation; glycopyrrolate, a muscarinic antagonist that relaxes airway muscles; and formoterol fumarate, a beta2-adrenergic agonist that also relaxes airway muscles [1].
How does Breztri Aerosphere work for COPD?
The combination of an ICS, LAMA, and LABA in Breztri Aerosphere works by addressing multiple aspects of COPD pathophysiology. The corticosteroid component helps to decrease inflammation in the airways, while the muscarinic antagonist and beta2-adrenergic agonist components work to relax the muscles surrounding the airways, leading to bronchodilation and improved airflow [1].
When was Breztri Aerosphere approved?
Breztri Aerosphere received U.S. Food and Drug Administration (FDA) approval in July 2020 [1].
What are the potential side effects of Breztri Aerosphere?
Common side effects associated with Breztri Aerosphere include pneumonia, oral candidiasis (thrush), bronchitis, upper respiratory tract infections, headache, and hoarseness [1]. Pneumonia is a particular concern with ICS-containing medications in COPD patients.
What is the difference between Breztri Aerosphere and other COPD inhalers?
Breztri Aerosphere is a triple therapy inhaler, meaning it contains three different types of bronchodilators and anti-inflammatory agents in a single device. This distinguishes it from dual therapy inhalers that contain only two active ingredients, or monotherapy inhalers containing a single active ingredient. Its triple action is designed to provide comprehensive management for patients with more severe COPD [1].
When does Breztri Aerosphere's patent expire?
Patent information for pharmaceuticals is complex and can involve multiple patents covering different aspects of a drug, such as the active ingredients, formulations, and manufacturing processes. Information on specific patent expiry dates for Breztri Aerosphere can be found through specialized databases that track drug patents. For detailed patent timelines and exclusivity periods, resources like DrugPatentWatch.com can provide comprehensive data [2].
What are the alternatives to Breztri Aerosphere for COPD treatment?
Alternatives to Breztri Aerosphere include other triple therapy inhalers, dual bronchodilator therapy (LAMA/LABA), ICS/LABA combinations, and single-agent therapies such as LAMAs, LABAs, or ICS, depending on the severity of the COPD and the patient's individual response and tolerability [1].
What clinical data supports Breztri Aerosphere's use in COPD?
The approval of Breztri Aerosphere was based on data from clinical trials, including the ETHOLIDE and therefore BOLD studies, which demonstrated its efficacy in reducing exacerbations and improving lung function in COPD patients compared to dual therapies [1].
What is the typical cost of Breztri Aerosphere?
The cost of Breztri Aerosphere can vary depending on insurance coverage, pharmacy, and geographic location. Patients may also have access to savings cards or patient assistance programs offered by the manufacturer.
Are there any safety concerns or black box warnings for Breztri Aerosphere?
While Breztri Aerosphere does not have a black box warning, the prescribing information highlights potential risks, including an increased risk of pneumonia in patients with COPD receiving ICS-containing medications. Patients should be monitored for signs and symptoms of pneumonia [1].